

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S2	1589	wong-s\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:57
S9	2	ludtke-j\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S8	63	monahan-sea\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S7	115	monahan-s\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S6	257	wolff-jo\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S5	0	wolff-jon.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S4	578	wolff-j\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S3	1	wong-so.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:58
S14	11	sebestyen-m\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:59

S13	9	wakefield-darr\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:59
S12	86	wakefield-d\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:59
S11	10	higgs-l\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:59
S10	1	higgs-lo\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 07:59
S1	12	sokoloff-a\$.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 08:07
S15	5	"6103239"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 08:15
S16	6	"444662".ap.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 13:24
S17	4424	"T7" SAME phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/07 13:25
S18	4	"T7" SAME phage AND tail ADJ fiber ADJ protein	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:01
L1	0	514/12.ccls. AND "T7" ADJ phage SAME interferon	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:02

L3	43	514/44.ccls. AND "T7" ADJ phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:03
L2	45	514/12.ccls. AND "T7" ADJ phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:03
L4	0	514/44.ccls. AND "T7" ADJ phage AND interferon.ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:04
L5	14	514/44.ccls. AND "T7" ADJ phage AND interferon	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:10
L6	0	hepatocyte SAME "T7" ADJ phage SAME interferon	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:11
L7	2	hepatocyte SAME "T7" ADJ phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:35
L8	0	530/300,350.ccls. AND hepatocyte SAME "T7" ADJ phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:36
L9	6	530/300,350.ccls. AND hepatocyte AND "T7" ADJ phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:39
L10	6	interferon SAME hepatocyte AND "T7" ADJ phage	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 09:59
L11	7	"782075".ap.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 10:19

L12	363	"T7" SAME liver	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 10:20
L13	29	"T7" SAME liver SAME target\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 11:26
L14	2	drug AND targeting AND conjugate AND interferon AND "T7" ADJ protein	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 11:27
L16	0	drug SAME targeting AND conjugate SAME interferon SAME "T7"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 11:28
L15	0	drug SAME targeting AND conjugate SAME interferon SAME "T7" ADJ protein	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/04/15 11:28

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653aud

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005

⇒ index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

THE BRUGMAN REC  
COST IN U.S. DOLLARS

**FULL ESTIMATED COST**

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> bacteriophage(w)T7 AND conjugate  
BACTERIOPHAGE(W)T7 IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s bacteriophage(w)T7 AND conjugate

1	FILE	AGRICOLA
1	FILE	BIOBUSINESS
1	FILE	BIOENG
3	FILE	BIOSIS
1	FILE	BIOTECHABS
1	FILE	BIOTECHDS
4	FILE	BIOTECHNO
10	FILE	CAPLUS
6	FILE	DGENE

29 FILES SEARCHED...

4	FILE	EMBASE
1	FILE	ESBIOBASE
1	FILE	FEDRIP
1	FILE	FSTA
1	FILE	GENBANK
2	FILE	IFIPAT
1	FILE	LIFESCI
8	FILE	MEDLINE
1	FILE	PASCAL
1	FILE	PROMT

61 FILES SEARCHED...

4	FILE	SCISEARCH
3	FILE	TOXCENTER
1039	FILE	USPATFULL
52	FILE	USPAT2

23 FILES HAVE ONE OR MORE ANSWERS, 75 FILES SEARCHED IN STNINDEX

L1 QUE BACTERIOPHAGE(W) T7 AND CONJUGATE

=> d rank

F1	1039	USPATFULL
F2	52	USPAT2
F3	10	CAPLUS
F4	8	MEDLINE
F5	6	DGENE
F6	4	BIOTECHNO
F7	4	EMBASE
F8	4	SCISEARCH
F9	3	BIOSIS
F10	3	TOXCENTER
F11	2	IFIPAT
F12	1	AGRICOLA
F13	1	BIOBUSINESS
F14	1	BIOENG

F15	1	BIOTECHABS
F16	1	BIOTECHDS
F17	1	ESBIOBASE
F18	1	FEDRIP
F19	1	FSTA
F20	1	GENBANK
F21	1	LIFESCI
F22	1	PASCAL
F23	1	PROMT

FILE 'USPATFULL' ENTERED AT 11:00:08 ON 15 APR 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 11:00:08 ON 15 APR 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:00:08 ON 15 APR 2005

FILE 'DGENE' ENTERED AT 11:00:08 ON 15 APR 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 11:00:08 ON 15 APR 2005  
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:00:08 ON 15 APR 2005  
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:00:08 ON 15 APR 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005  
Copyright (c) 2005 The Thomson Corporation

=> s bacteriophage(w)T7 AND conjugate  
L2 1078 BACTERIOPHAGE(W) T7 AND CONJUGATE

=> s interferon  
L3 642685 INTERFERON

=> S L2 AND L3

THE ELL AND ETC

4 FILES SEARCHED...

→ dup nom 14

=> dup rem 14

=> dup rem 14  
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L4  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)

⇒ d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W)T7 AND CONJUGATE

-----

1 FILE AGRICOLA  
1 FILE BIOBUSINESS  
1 FILE BIOENG  
3 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
4 FILE BIOTECHNO  
10 FILE CAPLUS  
6 FILE DGENE  
4 FILE EMBASE  
1 FILE ESBIOBASE  
1 FILE FEDRIP  
1 FILE FSTA  
1 FILE GENBANK  
2 FILE IFIPAT  
1 FILE LIFESCI  
8 FILE MEDLINE  
1 FILE PASCAL  
1 FILE PROMT  
4 FILE SCISEARCH  
3 FILE TOXCENTER  
1039 FILE USPATFULL  
52 FILE USPAT2

L1 QUE BACTERIOPHAGE(W) T7 AND CONJUGATE

-----

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005

L2 1078 S BACTERIOPHAGE(W)T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W)T7(W) PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)

=> s wolff,j?/au  
L7 6452 WOLFF,J?/AU

=> dup rem L7  
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING IS APPROXIMATELY 23% COMPLETE FOR L7  
PROCESSING IS APPROXIMATELY 60% COMPLETE FOR L7  
PROCESSING COMPLETED FOR L7  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)

=> s L8 AND L6  
L9 1 L8 AND L6

=> d 19 ibib ti abs

L9 ANSWER 1 OF 1 USPATFULL on STN  
ACCESSION NUMBER: 2004:39284 USPATFULL  
TITLE: Compounds for targeting hepatocytes in vivo  
INVENTOR(S): Sokoloff, Alexander V., Madison, WI, UNITED STATES  
Wong, So, Oregon, WI, UNITED STATES  
Wolff, Jon A., Madison, WI, UNITED STATES

Monahan, Sean D., Madison, WI, UNITED STATES  
Ludtke, James, Deerfield, WI, UNITED STATES  
Higgs, Lori, Madison, WI, UNITED STATES  
Wakefield, Darren, Fitchburg, WI, UNITED STATES  
Sebestyen, Magdolna G., Madison, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004029826	A1	20040212
APPLICATION INFO.:	US 2003-633808	A1	20030804 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-401167P	20020805 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Mark K. Johnson, Mirus Corporation, 505 S. Rosa Rd., Madison, WI, 53719	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	2191	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compounds for targeting hepatocytes in vivo  
AB We describe compounds that bind to and are internalized by hepatocytes.  
Association of these compounds to other molecules or complexes can be  
used to target the molecules or complexes to hepatocytes in vivo or in  
vitro.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,  
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,  
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,  
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W)T7 AND CONJUGATE

1	FILE AGRICOLA
1	FILE BIOBUSINESS
1	FILE BIOENG
3	FILE BIOSIS
1	FILE BIOTECHABS
1	FILE BIOTECHDS
4	FILE BIOTECHNO
10	FILE CAPLUS
6	FILE DGENE
4	FILE EMBASE
1	FILE ESBIOBASE
1	FILE FEDRIP
1	FILE FSTA
1	FILE GENBANK
2	FILE IFIPAT
1	FILE LIFESCI
8	FILE MEDLINE
1	FILE PASCAL
1	FILE PROMT
4	FILE SCISEARCH
3	FILE TOXCENTER

1039 FILE USPATFULL  
52 FILE USPAT2  
L1 QUE BACTERIOPHAGE(W) T7 AND CONJUGATE  
-----

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005

L2 1078 S BACTERIOPHAGE(W) T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W) T7 (W) PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)  
L7 6452 S WOLFF, J?/AU  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)  
L9 1 S L8 AND L6

=> s covalent AND L4  
L10 332 COVALENT AND L4

=> s hepatocyte AND L10  
L11 177 HEPATOCYTE AND L10

=> dup rem L11  
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L11  
L12 177 DUP REM L11 (0 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABAB, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W) T7 AND CONJUGATE  
-----

1 FILE AGRICOLA  
1 FILE BIOBUSINESS  
1 FILE BIOENG  
3 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
4 FILE BIOTECHNO  
10 FILE CAPLUS  
6 FILE DGENE  
4 FILE EMBASE  
1 FILE ESBIOBASE  
1 FILE FEDRIP  
1 FILE FSTA  
1 FILE GENBANK  
2 FILE IFIPAT  
1 FILE LIFESCI  
8 FILE MEDLINE  
1 FILE PASCAL  
1 FILE PROMT  
4 FILE SCISEARCH  
3 FILE TOXCENTER  
1039 FILE USPATFULL  
52 FILE USPAT2  
L1 QUE BACTERIOPHAGE(W) T7 AND CONJUGATE  
-----

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005

L2 1078 S BACTERIOPHAGE(W)T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W)T7(W) PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)  
L7 6452 S WOLFF, J?/AU  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)  
L9 1 S L8 AND L6  
L10 332 S COVALENT AND L4  
L11 177 S HEPATOCYTE AND L10  
L12 177 DUP REM L11 (0 DUPLICATES REMOVED)

=> d 112 ibib ti abs 170-177

L12 ANSWER 170 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 2002:16878 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of lung cancer  
INVENTOR(S): Harlocker, Susan L., Seattle, WA, UNITED STATES  
Wang, Tongtong, Medina, WA, UNITED STATES  
Bangur, Chaitanya S., Seattle, WA, UNITED STATES  
Klee, Jennifer I., Seattle, WA, UNITED STATES  
Switzer, Ann, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002009758	A1	20020124
APPLICATION INFO.:	US 2001-866562	A1	20010525 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207485P	20000526 (60)
	US 2000-230475P	20000906 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7045	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compositions and methods for the therapy and diagnosis of lung cancer  
AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly lung cancer, are disclosed. Illustrative compositions  
comprise one or more lung tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly lung cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 171 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 2001:191105 USPATFULL  
TITLE: Agouti polypeptide compositions  
INVENTOR(S): Woychik, Richard P., Orinda, CA, United States  
Bultman, Scott J., Lakewood, OH, United States  
Michaud, Edward J., Kingston, TN, United States  
PATENT ASSIGNEE(S): UT-Battelle, LLC, Oak Ridge, TN, United States (U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6310034	B1	20011030
APPLICATION INFO.:	US 1998-34088		19980303 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-64385, filed on 21 May 1993, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Kammerer, Elyabik C.  
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson  
NUMBER OF CLAIMS: 34  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 83 Drawing Figure(s); 41 Drawing Page(s)  
LINE COUNT: 10935  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Agouti polypeptide compositions  
AB Disclosed are methods and compositions comprising novel agouti polypeptides and the polynucleotides which encode them. Also disclosed are DNA segments encoding these proteins derived from human and murine cell lines, and the use of these polynucleotides and polypeptides in a variety of diagnostic and therapeutic applications. Methods, compositions, kits, and devices are also provided for identifying compounds which are inhibitors of agouti activity, and for altering fatty acid synthetase activity and intracellular calcium levels in transformed cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 172 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 2000:61580 USPATFULL  
TITLE: Method for using lipoprotein associated coagulation inhibitor to treat sepsis  
INVENTOR(S): Creasey, Abla A., Piedmont, CA, United States  
Broze, George J., Ladue, MO, United States  
PATENT ASSIGNEE(S): Washington University & Chiron Corp., United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6063764		20000516
APPLICATION INFO.:	US 1995-472761		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224118, filed on 29 Mar 1994, now abandoned which is a continuation of Ser. No. US 1993-20427, filed on 22 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-897135, filed on 11 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1994-253427, filed on 2 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-4505, filed on 13 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-891947, filed on 1 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1994-270455, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1992-891947, filed on 1 Jun 1992, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Tsang, Cecilia  
ASSISTANT EXAMINER: Delacroix-Muirheid, C.  
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.  
NUMBER OF CLAIMS: 45

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 5 Drawing Page(s)  
LINE COUNT: 2568  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for using lipoprotein associated coagulation inhibitor to treat sepsis  
AB A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to patients. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 173 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 2000:43946 USPATFULL  
TITLE: Human PAK65  
INVENTOR(S): Abo, Arie, San Francisco, CA, United States  
Martin, George A., Berkeley, CA, United States  
PATENT ASSIGNEE(S): Onyx Pharmaceuticals, Inc., Richmond, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6048706		20000411
APPLICATION INFO.:	US 1998-108262		19980701 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-918509, filed on 22 Aug 1997 which is a continuation of Ser. No. US 1997-780853, filed on 10 Jan 1997, now patented, Pat. No. US 5698428, issued on 16 Dec 1997 which is a continuation of Ser. No. US 1995-475682, filed on 7 Jun 1995, now patented, Pat. No. US 5605825, issued on 25 Feb 1997 which is a continuation of Ser. No. US 1995-369780, filed on 6 Jan 1995, now patented, Pat. No. US 5518911, issued on 21 May 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Giotta, Gregory, Ashton, Esq., Nina M.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	3072		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Human PAK65  
AB A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune

diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 174 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 2000:4627 USPATFULL  
TITLE: Human PAK65  
INVENTOR(S): Abo, Arie, San Francisco, CA, United States  
Martin, George A., Berkeley, CA, United States  
PATENT ASSIGNEE(S): Onyx Pharmaceuticals, Inc., Richmond, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013464		20000111
APPLICATION INFO.:	US 1997-918509		19970822 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-780833, filed on 10 Jan 1997, now patented, Pat. No. US 5698428 which is a continuation of Ser. No. US 1995-475682, filed on 7 Jun 1995, now patented, Pat. No. US 5605825 which is a continuation of Ser. No. US 1995-369780, filed on 6 Jan 1995, now patented, Pat. No. US 5518911		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Wax, Robert A.  
ASSISTANT EXAMINER: Stole, Einar  
LEGAL REPRESENTATIVE: Cooley Godward LLP, Giotta, Gregory J.  
NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 13 Drawing Page(s)  
LINE COUNT: 3103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Human PAK65  
AB A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac 1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 175 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 97:117938 USPATFULL  
TITLE: Human PAK65  
INVENTOR(S): Abo, Arie, San Francisco, CA, United States  
Martin, George A., Berkeley, CA, United States  
PATENT ASSIGNEE(S): Onyx Pharmaceuticals, Inc., Richmond, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

-----  
PATENT INFORMATION: US 5698445 19971216  
APPLICATION INFO.: US 1996-636036 19960422 (8)  
RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-369780, filed on 6 Jan  
1995, now patented, Pat. No. US 5518911  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Wax, Robert A.  
ASSISTANT EXAMINER: Hobbs, Lisa J.  
LEGAL REPRESENTATIVE: Ashton, Nina M., Giotta, Gregory J. Onyx  
Pharmaceuticals, Inc.  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 13 Drawing Page(s)  
LINE COUNT: 2965  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Human PAK65

AB A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 176 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 97:117922 USPATFULL  
TITLE: Human PAK65  
INVENTOR(S): Abo, Arie, San Francisco, CA, United States  
Martin, George A., Berkeley, CA, United States  
PATENT ASSIGNEE(S): Onyx Pharmaceuticals, Inc., Richmond, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5698428		19971216
APPLICATION INFO.:	US 1997-780833		19970110 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-475682, filed on 7 Jun 1995, now patented, Pat. No. US 5605825 which is a continuation of Ser. No. US 1995-369780, filed on 6 Jan 1995, now patented, Pat. No. US 5518911		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Ashton, Nina M., Giotta, Ph.D. FI Onyx Pharmaceuticals Inc., Gregory J.		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	2970		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Human PAK65

AB A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 177 OF 177 USPATFULL on STN  
ACCESSION NUMBER: 96:43564 USPATFULL  
TITLE: Human PAK65  
INVENTOR(S): Abo, Arie, San Francisco, CA, United States  
                  Martin, George A., Berkeley, CA, United States  
PATENT ASSIGNEE(S): Onyx Pharmaceuticals, Inc., Richmond, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5518911		19960521
APPLICATION INFO.:	US 1995-369780		19950106 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Hobbs, Lisa J.		
LEGAL REPRESENTATIVE:	Giotta, Greg, Mendlein, John D., Torchia, Timothy E.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	2892		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Human PAK65

AB A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W)T7 AND CONJUGATE

-----  
1 FILE AGRICOLA  
1 FILE BIOBUSINESS  
1 FILE BIOENG  
3 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
4 FILE BIOTECHNO  
10 FILE CAPLUS  
6 FILE DGENE  
4 FILE EMBASE  
1 FILE ESBIOBASE  
1 FILE FEDRIP  
1 FILE FSTA  
1 FILE GENBANK  
2 FILE IFIPAT  
1 FILE LIFESCI  
8 FILE MEDLINE  
1 FILE PASCAL  
1 FILE PROMT  
4 FILE SCISEARCH  
3 FILE TOXCENTER  
1039 FILE USPATFULL  
52 FILE USPAT2  
QUE BACTERIOPHAGE(W) T7 AND CONJUGATE

L1

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005

L2 1078 S BACTERIOPHAGE(W)T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W)T7(W)PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)  
L7 6452 S WOLFF, J?/AU  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)  
L9 1 S L8 AND L6  
L10 332 S COVALENT AND L4  
L11 177 S HEPATOCYTE AND L10  
L12 177 DUP REM L11 (0 DUPLICATES REMOVED)

=> s drug AND targeting AND conjugate AND interferon AND T7

6 FILES SEARCHED...

L13 4481 DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7

=> s drug AND targeting AND conjugate AND interferon AND T7(W)protein  
4 FILES SEARCHED...

6 FILES SEARCHED...

L14 8 DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7(W) PROTEI  
N

=> d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPUS, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W)T7 AND CONJUGATE

-----  
1 FILE AGRICOLA  
1 FILE BIOBUSINESS  
1 FILE BIOENG  
3 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
4 FILE BIOTECHNO  
10 FILE CAPLUS  
6 FILE DGENE  
4 FILE EMBASE  
1 FILE ESBIOBASE  
1 FILE FEDRIP  
1 FILE FSTA  
1 FILE GENBANK  
2 FILE IFIPAT  
1 FILE LIFESCI  
8 FILE MEDLINE  
1 FILE PASCAL  
1 FILE PROMT  
4 FILE SCISEARCH  
3 FILE TOXCENTER  
1039 FILE USPATFULL  
52 FILE USPAT2  
L1 QUE BACTERIOPHAGE(W) T7 AND CONJUGATE  
-----

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005  
L2 1078 S BACTERIOPHAGE(W)T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W)T7(W) PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)  
L7 6452 S WOLFF, J?/AU  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)  
L9 1 S L8 AND L6  
L10 332 S COVALENT AND L4  
L11 177 S HEPATOCYTE AND L10  
L12 177 DUP REM L11 (0 DUPLICATES REMOVED)  
L13 4481 S DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7  
L14 8 S DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7(W) PROT

=> dup rem L14

DUPLICATE IS NOT AVAILABLE IN 'DGENE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L14

L15 8 DUP REM L14 (0 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,  
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,  
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W)T7 AND CONJUGATE

-----  
1 FILE AGRICOLA  
1 FILE BIOBUSINESS  
1 FILE BIOENG  
3 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
4 FILE BIOTECHNO  
10 FILE CAPLUS  
6 FILE DGENE  
4 FILE EMBASE  
1 FILE ESBIOSBASE  
1 FILE FEDRIP  
1 FILE FSTA  
1 FILE GENBANK  
2 FILE IFIPAT  
1 FILE LIFESCI  
8 FILE MEDLINE  
1 FILE PASCAL  
1 FILE PROMT  
4 FILE SCISEARCH  
3 FILE TOXCENTER  
1039 FILE USPATFULL  
52 FILE USPAT2  
L1 QUE BACTERIOPHAGE(W) T7 AND CONJUGATE  
-----

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH,  
BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005

L2 1078 S BACTERIOPHAGE(W)T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W)T7 (W) PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)  
L7 6452 S WOLFF, J?/AU  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)  
L9 1 S L8 AND L6  
L10 332 S COVALENT AND L4  
L11 177 S HEPATOCYTE AND L10  
L12 177 DUP REM L11 (0 DUPLICATES REMOVED)  
L13 4481 S DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7  
L14 8 S DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7 (W) PROT  
L15 8 DUP REM L14 (0 DUPLICATES REMOVED)

=> d l15 ibib ti abs 1-8

L15 ANSWER 1 OF 8 USPATFULL on STN  
ACCESSION NUMBER: 2004:286246 USPATFULL  
TITLE: THAP proteins as nuclear receptors for chemokines and  
roles in transcriptional regulation, cell proliferation  
and cell differentiation  
INVENTOR(S): Girard, Jean-Philippe, Rebigue, FRANCE  
Amalric, Francois, Toulouse, FRANCE  
Roussigne, Myriam, La Bastide sur L'Hers, FRANCE  
Clouaire, Thomas, Toulouse, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004224408	A1	20041111

APPLICATION INFO.: US 2003-733878 A1 20031210 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-485027P	20030703 (60)
	US 2002-432699P	20021210 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	212	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	36	Drawing Page(s)
LINE COUNT:	14467	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation  
AB The invention relates to genes and proteins of the THAP family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to uses of THAP-type chemokine-binding agents, such as THAP-family proteins, as a nuclear receptors for a chemokines and to methods for the modulation (stimulation or inhibition) of transcription, cell proliferation and cell differentiation as well as methods for identifying for compounds which modulate THAP-chemokine interactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 2 OF 8 USPATFULL on STN  
ACCESSION NUMBER: 2004:144517 USPATFULL  
TITLE: Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof  
INVENTOR(S): Zagursky, Robert John, Victor, NY, UNITED STATES  
Masi, Amy Wadham, Caledonia, NY, UNITED STATES  
Green, Bruce Arthur, New City, NY, UNITED STATES  
Chakravarti, Deb Narayan, Claremont, CA, UNITED STATES  
Russell, David Parrish, Canandaigua, NY, UNITED STATES  
Wooters, Joseph Lawrence, Brighton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004110181	A1	20040610
APPLICATION INFO.:	US 2004-474776	A1	20040105 (10)
	WO 2002-US11524		20020412
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940		
NUMBER OF CLAIMS:	105		
EXEMPLARY CLAIM:	1		
LINE COUNT:	6388		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof  
AB The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode polypeptides that are surface localized on Streptococcus pneumoniae. Thus, the invention relates to Streptococcus pneumoniae open reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by the Streptococcus pneumoniae open reading frames, vectors comprising open reading frame sequences and cells or animals transformed

with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosing *Streptococcus pneumoniae* infection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with *Streptococcus pneumoniae*. In particular embodiments, the immunogenic compositions are used for the treatment or prevention of systemic diseases which are induced or exacerbated by *Streptococcus pneumoniae*. In other embodiments, the immunogenic compositions are used for the treatment or prevention of non-systemic diseases, particularly of the otitis media, which are induced or exacerbated by *Streptococcus pneumoniae*.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2004:50778 USPATFULL  
TITLE: Gene expression in bladder tumors  
INVENTOR(S): Orntoft, Torben F., Aabyhoj, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038207	A1	20040226
APPLICATION INFO.:	US 2001-951968	A1	20010914 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	28561		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Gene expression in bladder tumors

AB Methods for analyzing tumor cells, particularly bladder tumor cells employ gene expression analysis of samples. Gene expression patterns are formed and compared to reference patterns. Alternatively gene expression patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 8 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904

APPLICATION INFO.: US 2002-99926 A1 20020314 (10)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-33528, filed  
 on 26 Dec 2001, PENDING Continuation-in-part of Ser.  
 No. US 2001-920300, filed on 31 Jul 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8531	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compositions and methods for the therapy and diagnosis of colon cancer  
 AB Compositions and methods for the therapy and diagnosis of cancer,  
 particularly colon cancer, are disclosed. Illustrative compositions  
 comprise one or more colon tumor polypeptides, immunogenic portions  
 thereof, polynucleotides that encode such polypeptides, antigen  
 presenting cell that expresses such polypeptides, and T cells that are  
 specific for cells expressing such polypeptides. The disclosed  
 compositions are useful, for example, in the diagnosis, prevention  
 and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 8 USPATFULL on STN  
 ACCESSION NUMBER: 2003:106233 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis  
 of pancreatic cancer  
 INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
 Kalos, Michael D., Seattle, WA, UNITED STATES  
 Lodes, Michael J., Seattle, WA, UNITED STATES  
 Persing, David H., Redmond, WA, UNITED STATES  
 Hepler, William T., Seattle, WA, UNITED STATES  
 Jiang, Yuqiu, Kent, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073144	A1	20030417
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	

NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compositions and methods for the therapy and diagnosis of pancreatic cancer  
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 6 OF 8 USPATFULL on STN  
ACCESSION NUMBER: 2002:243051 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer  
INVENTOR(S): Algaté, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	

NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
LINE COUNT: 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compositions and methods for the therapy and diagnosis of ovarian cancer  
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 7 OF 8 USPATFULL on STN  
ACCESSION NUMBER: 2002:242791 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002131971	A1	20020919
APPLICATION INFO.:	US 2001-33528	A1	20011226 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 8083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compositions and methods for the therapy and diagnosis of colon cancer  
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 8 OF 8 USPATFULL on STN  
ACCESSION NUMBER: 2002:67187 USPATFULL  
TITLE: Novel P-selectin glycoprotein ligand (PSGL-1) binding protein and uses therefor  
INVENTOR(S): Lorenz, Meike, Arlington, MA, UNITED STATES  
Kriz, Ron, Hudson, MA, UNITED STATES  
Weich, Nadine, Brookline, MA, UNITED STATES  
Shaw, Gray D., Milton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037840	A1	20020328
APPLICATION INFO.:	US 6852497	B2	20050208
	US 2001-816697	A1	20010323 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-192104P	20000324 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3996	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Novel P-selectin glycoprotein ligand (PSGL-1) binding protein and uses therefor

AB The invention provides isolated nucleic acids molecules, designated SLIC-1 nucleic acid molecules, which encode novel P-selectin glycoprotein ligand (PSGL-1) binding molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLIC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLIC-1 gene has been introduced or disrupted. The invention still further provides isolated SLIC-1 proteins, fusion proteins, antigenic peptides and anti-SLIC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:57:53 ON 15 APR 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDHS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:58:01 ON 15 APR 2005  
SEA BACTERIOPHAGE(W)T7 AND CONJUGATE

-----  
1 FILE AGRICOLA  
1 FILE BIOBUSINESS  
1 FILE BIOENG  
3 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDHS  
4 FILE BIOTECHNO  
10 FILE CAPLUS  
6 FILE DGENE  
4 FILE EMBASE  
1 FILE ESBIOBASE  
1 FILE FEDRIP  
1 FILE FSTA  
1 FILE GENBANK  
2 FILE IFIPAT  
1 FILE LIFESCI  
8 FILE MEDLINE  
1 FILE PASCAL  
1 FILE PROMT  
4 FILE SCISEARCH  
3 FILE TOXCENTER  
1039 FILE USPATFULL  
52 FILE USPAT2  
QUE BACTERIOPHAGE(W) T7 AND CONJUGATE

L1

FILE 'USPATFULL, CAPLUS, MEDLINE, DGENE, BIOTECHNO, EMBASE, SCISEARCH, BIOSIS' ENTERED AT 11:00:08 ON 15 APR 2005

L2 1078 S BACTERIOPHAGE(W)T7 AND CONJUGATE  
L3 642685 S INTERFERON  
L4 446 S L2 AND L3  
L5 0 S BACTERIOPHAGE(W)T7(W) PROTEIN AND INTERFERON  
L6 446 DUP REM L4 (0 DUPLICATES REMOVED)  
L7 6452 S WOLFF, J?/AU  
L8 3396 DUP REM L7 (3056 DUPLICATES REMOVED)  
L9 1 S L8 AND L6  
L10 332 S COVALENT AND L4  
L11 177 S HEPATOCYTE AND L10  
L12 177 DUP REM L11 (0 DUPLICATES REMOVED)

L13 4481 S DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7  
L14 8 S DRUG AND TARGETING AND CONJUGATE AND INTERFERON AND T7 (W) PROT  
L15 8 DUP REM L14 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.48	112.05

STN INTERNATIONAL LOGOFF AT 11:20:10 ON 15 APR 2005